Orexin receptor antagonism: An ascending multiple-dose study with almorexant

Journal of Psychopharmacology

Volumn 26, Issue 8, 2012, Pages 1071-1080

  Hoever, Petra ^a   De Haas, Sanne L ^b   Dorffner, Georg ^c,d   Chiossi, Eleonora ^a   Van Gerven, Joop M ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Vienna   (Austria)

Author keywords

Almorexant; insomnia; orexin receptor antagonist; pharmacodynamics; pharmacokinetics

Indexed keywords

ALMOREXANT; PLACEBO;

ADULT; ALERTNESS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLURRED VISION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MOTOR COORDINATION; MULTIPLE DRUG DOSE; MUSCLE WEAKNESS; MYOCLONUS; NORMAL HUMAN; PARASOMNIA; PHARMACODYNAMICS; PRIORITY JOURNAL; REM SLEEP; SLEEP STAGE; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNCONSCIOUSNESS; VISUOMOTOR COORDINATION; XEROSTOMIA;

ACETAMIDES; ADOLESCENT; ADULT; BRAIN WAVES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; ISOQUINOLINES; MALE; POLYSOMNOGRAPHY; PSYCHOMOTOR PERFORMANCE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SLEEP STAGES;

EID: 84864144743     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112448946     Document Type: Article

References (34)

1. Anderer P, Gruber G, Parapatics S, et al. An E-health solution for automatic sleep classification according to Rechtschaffen and Kales: validation study of the Somnolyzer 24 x 7 utilizing the Siesta database. Neuropsychobiology. 2005 ; 51: 115-133
2. Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol. 2008 ; 4: 175-192
3. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Brit J Med Psychol. 1974 ; 47: 211-218
4. Borland RG, Nicholson AN. Human performance after barbiturate (heptabarbitone). Br J Clin Pharmacol. 1974 ; 1: 209-215
5. Bowdle TA, Radant AD, Cowley DS, et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 1998 ; 88: 82-88
6. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007 ; 13: 150-155
7. Cruz H, Hoever P, Fiala-Buskies S, et al. Effect of ketoconazole on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist. Paper at American Association of Pharmaceutical Scientists Annual Meeting ; 2011 Washington DC, USA ; 2011..
8. Cysneiros RM, Farkas D, Harmatz JS, et al. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther. 2007 ; 82: 54-62
9. De Haas SL, Franson KL, Schmitt JA, et al. J Psychopharmacol. 2009 1498 ; 23: 625-632
10. De Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998 ; 95: 322-327
11. Ganjavi H, Shapiro CM. Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure. J Neuropsychiatry Clin Neurosci. 2007 ; 19: 413-419
12. Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J. 1995 ; 29: 1039-1048
13. Herrmann W, Irrgang U. An absolute must in clinico-pharmacological research: pharmaco-electroencephalography, its possibilities and limitations. Pharmacopsychiatry. 1983 ; 16: 134-142
14. Hoch M, Hoever P, Alessi F, et al. Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjects. Pharmacology. 2011a ; 88: 121-126
15. Hoch M, Hoever P, Haschke M, et al. Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects. J Clin Pharmacol. 2011b ; 51: 1116-1121
16. Hoch M, Hoever P, Zisowsky J, et al. Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects. Pharmacology. 2012 ; 89: 53-57
17. Hoever P, De Haas S, Winkler J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther. 2010 ; 87: 593-600
18. Hoever P, Dorffner G, Benes H, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof of concept clinical trial. Clin Pharmacol Ther. 2012 ; 96: 975-985
19. Jurcak V, Tsuzuki D, Dan I. 10/20, 10/10, and 10/5 systems revisited: their validity as relative head-surface-based positioning systems. Neuroimage. 2007 ; 34: 1600-1611
20. Kilduff TS, Peyron C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci. 2000 ; 23: 359-365
21. Lemmer B. Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol. 1999 ; 51: 887-890
22. Nishino S. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders. Expert Opin Investig Drugs. 2007 ; 16: 1785-1797
23. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000 ; 355: 39-40
24. Penzel T, Hirshkowitz M, Harsh J, et al. Digital analysis and technical specifications. J Clin Sleep Med. 2007 ; 3: 109-120
25. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000 ; 6: 991-997
26. Rechtschaffen A, Kales A A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington, DC, USA: Public Health Service, U.S. Government Printing Office ; 1968 :
27. Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl). 1994 ; 116: 130-134
28. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998 ; 92: 573-585
29. Saletu B, Kindshofer G, Anderer P, et al. Short-term sleep laboratory studies with cinolazepam in situational insomnia induced by traffic noise. Int J Clin Pharmacol Res. 1987 ; 7: 407-418
30. Svetnik V, Ma J, Soper KA, et al. Evaluation of automated and semi-automated scoring of polysomnographic recordings from a clinical trial using zolpidem in the treatment of insomnia. Sleep. 2007 ; 30: 1562-1574
31. Tsujino N, Sakurai T. Orexin/Hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev. 2009 ; 61: 162-176
32. Van Steveninck AL, Schoemaker HC, Pieters MS, et al. A study comparing the sensitivities of adaptive tracking, eye movement analysis and visual analogue lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther. 1991 ; 50: 172-180
33. Wafford KA, Ebert B. Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nat Rev Drug Discov. 2008 ; 7: 530-540
34. Zhdanova IV. Advances in the management of insomnia. Expert Opin Pharmacother. 2004 ; 5: 1573-1579